21339-74-2 Usage
General Description
Methyl 4-amino-2,5-dimethylbenzoate is an organic compound with the chemical formula C10H13NO2. It is a white crystalline solid that is commonly used as a reagent in organic synthesis and pharmaceutical research. This chemical is often used as an intermediate in the production of various pharmaceuticals, such as analgesics and anti-inflammatory drugs. It is also used as a building block for the synthesis of other organic compounds, and has applications in the manufacturing of dyes and pigments. However, it is important to handle this chemical with care, as it can be harmful if ingested or inhaled, and can cause skin and eye irritation.
Check Digit Verification of cas no
The CAS Registry Mumber 21339-74-2 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 2,1,3,3 and 9 respectively; the second part has 2 digits, 7 and 4 respectively.
Calculate Digit Verification of CAS Registry Number 21339-74:
(7*2)+(6*1)+(5*3)+(4*3)+(3*9)+(2*7)+(1*4)=92
92 % 10 = 2
So 21339-74-2 is a valid CAS Registry Number.
InChI:InChI=1/C10H13NO2/c1-6-5-9(11)7(2)4-8(6)10(12)13-3/h4-5H,11H2,1-3H3
21339-74-2Relevant articles and documents
FUNGICIDAL ARYL AMIDINES
-
, (2020/12/07)
This disclosure relates to aryl amidines of Formula I and their use as fungicides. One embodiment of the present disclosure is a use of a compound of Formula I, for protection of a plant against attack by a phytopathogenic organism or the treatment of a plant infested by a phytopathogenic organism, comprising the application of a compound of Formula I, or a composition comprising the compound to soil, a plant, a part of a plant, foliage, and/or roots.
Dialkylphenyl compounds having beta2 adrenergic receptor agonist and muscarinic receptor antagonist activity
-
Page/Page column 10, (2008/06/13)
This invention relates to compounds of formula I: wherein R1 and R2 are as defined in the specification, or a pharmaceutically acceptable salt or solvate or stereoisomer thereof. The invention also relates to pharmaceutical compositions and combinations comprising such compounds, processes and intermediates for preparing such compounds, and methods of using such compound to, for example, treat pulmonary disorders, such as chronic obstructive pulmonary disease and asthma.
